Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
June 13 2024 - 7:00AM
Business Wire
-- Three medical experts will join members of
Syros’ leadership team to provide an overview of HR-MDS patient
management, perspectives on the current and future treatment
landscape, and the opportunity for tamibarotene on Tuesday, June 25
at 11:00 a.m. ET --
-- Syros expects to report pivotal Phase 3 data
from SELECT-MDS-1 by mid-4Q 2024 --
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company
committed to advancing new standards of care for the frontline
treatment of hematologic malignancies, today announced that it will
host a webcast event with medical experts to discuss the unmet need
in higher-risk myelodysplastic syndrome (HR-MDS) and the
opportunity for tamibarotene to transform the care of newly
diagnosed patients with RARA gene overexpression. The event will
take place on Tuesday, June 25, 2024, from 11:00 a.m. – 12:30 p.m.
ET.
Syros is currently evaluating tamibarotene in SELECT-MDS-1, a
pivotal Phase 3 clinical trial in HR-MDS patients with RARA
overexpression, and in SELECT-AML-1, a Phase 2 clinical trial in
unfit acute myeloid leukemia (AML) patients with RARA
overexpression. Syros expects to report pivotal complete response
data from the SELECT-MDS-1 trial by the middle of the fourth
quarter of 2024 and will report clinical activity and tolerability
data from a prespecified analysis of over 40 patients from the
SELECT-AML-1 trial in the third quarter of 2024.
The webcast event will feature presentations from Amy DeZern,
M.D., M.H.S., Professor of Oncology and Medicine, Sidney Kimmel
Comprehensive Cancer Center at Johns Hopkins University School of
Medicine, Amer Zeidan, M.B.B.S., M.H.S., Chief, Hematologic
Malignancies, Yale Cancer Center and Smilow Cancer Hospital;
Associate Professor of Medicine (Hematology), Yale School of
Medicine and David Sallman, M.D., Myeloid Section Head and
Associate Member, Department of Malignant Hematology, H. Lee
Moffitt Cancer Center & Research Institute. The speakers will
provide a disease overview of HR-MDS, including current therapies
and approach to patient management, evaluation of patient outcomes
in HR-MDS trials, and the emerging treatment landscape and ongoing
areas of unmet need. In addition, members of Syros’ leadership team
will provide an overview of RARA overexpression and tamibarotene’s
mechanism of action, review the design of the pivotal SELECT-MDS-1
Phase 3 trial, and discuss previously presented clinical data
supporting the development of tamibarotene for HR-MDS and the
potential commercial opportunity.
There will be an opportunity for Q&A during the
presentation. Participants can register for the live webcast here.
For participants joining via conference call, please dial (800)
549-8228 (domestic) or (646) 564-2877 (international) and refer to
conference ID 68622. In addition, a live webcast of the
presentation will be available on the Investors & Media section
of the Syros website at www.syros.com. An archived replay of the
webcast will be available following the presentation.
About Syros Pharmaceuticals
Syros is committed to developing new standards of care for the
frontline treatment of patients with hematologic malignancies.
Driven by the motivation to help patients with blood disorders that
have largely eluded other targeted approaches, Syros is developing
tamibarotene, an oral selective RARα agonist in frontline patients
with higher-risk myelodysplastic syndrome and acute myeloid
leukemia with RARA gene overexpression. For more information, visit
www.syros.com and follow us on Twitter (@SyrosPharma) and
LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995, including without limitation statements regarding Syros’
clinical development plans, the progression of its clinical trials,
the timing to report clinical data, the ability to deliver benefit
to patients, and the commercial potential of tamibarotene. The
words “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “hope,” “intend,” “may,” “plan,” “potential,” “predict,”
“project,” “target,” “should,” “would,” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Actual
results or events could differ materially from the plans,
intentions and expectations disclosed in these forward-looking
statements as a result of various important factors, including
Syros’ ability to: advance the development of its programs under
the timelines it projects in current and future clinical trials;
demonstrate in any current and future clinical trials the requisite
safety, efficacy and combinability of its drug candidates; sustain
the response rates and durability of response seen to date with its
drug candidates; successfully develop a companion diagnostic test
to identify patients with the RARA biomarker; obtain and maintain
patent protection for its drug candidates and the freedom to
operate under third party intellectual property; obtain and
maintain necessary regulatory approvals; identify, enter into and
maintain collaboration agreements with third parties; manage
competition; manage expenses; raise the substantial additional
capital needed to achieve its business objectives; attract and
retain qualified personnel; and successfully execute on its
business strategies; risks described under the caption “Risk
Factors” in Syros’ Annual Report on Form 10-K for the year ended
December 31, 2023 and Quarterly Report on Form 10-Q for the quarter
ended March 31, 2024, each of which is on file with the Securities
and Exchange Commission; and risks described in other filings that
Syros makes with the Securities and Exchange Commission in the
future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240613264695/en/
Syros Contact Karen Hunady Director of Corporate
Communications & Investor Relations 1-857-327-7321
khunady@syros.com
Investor Contact Amanda Isacoff Precision AQ 212-362-1200
amanda.isacoff@precisionaq.com
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Nov 2024 to Dec 2024
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Dec 2023 to Dec 2024